

Autonomix Medical, Inc. (AMIX)

Nasdaq; healthcare; SIC 3841, Surgical & Medical Instruments & Apparatus; CIK 0001617867

Autonomix Medical, Inc.		
AMIX; healthcare		
Grade	None 3 of 14 inputs computable; 7 are required	Share price, twelve months to the rescan split-adjusted close; the letter is fixed at the rescan that set it 
Reliability	0.76 AUC filers with under \$12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025	
Peer failure rate	0.60% a year Item 1.03 bankruptcies, same asset band, 2012 to 2025	
Size band	under \$12.5M assets total assets \$7.6M	
Standard universe	outside revenue above \$1M and assets above \$10M	
Warnings	short runway, thin data, degenerate inputs not computable: dilution, distress, fortress balance sheet	
Inputs computable	3 of 14	
Graded from	filings received through Jun 15, 2026 116 days before the rescan; latest periodic filing 10-Q received Aug 13, 2026	
Last close	\$3.10 2026-10-08; market equity \$3.0M	
Price used in grade	None	

Letter at every rescan

Jan 21, 2012 to Oct 9, 2026; sector percentile, stronger toward the top; facts filed by each date only

A	
B	
C	
D	
E	
	20132014201520162017201820192020202120222023202420252026

Business, in the company's words

opening of Item 1 of the 10-K received May 27, 2026

We are a development-stage medical device company focused on advancing technologies for sensing and treating disorders of the nervous system. Our platform is designed to integrate high-sensitivity neural signal detection with targeted radiofrequency ("RF") ablation, enabling a "sense, treat, verify" approach intended to improve the precision and consistency of nerve-targeted therapies. The technology we have developed consists of a catheter-based system incorporating a proprietary microchip-enabled sensing architecture designed to detect low-amplitude neural signals from within the vascular system.

The fourteen inputs

lower percentile is stronger; equal-weighted sleeves

Input	Percentile, 0 to 100	Value	Peer median	Percentile	Peers	Period end
Profitability, sleeve percentile 8.4						
Gross profitability		not computable	32.2%		one or more required annual facts are missing	

Return on invested capital		not computable	9.3%			one or more required annual facts are missing
Accruals ratio		(50.9%)	(6.6%)	8.4	811	2026-03-31
Gross margin stability, five years		not computable	2.8 pts			five annual gross margins are required; found 0
Solvency, sleeve percentile 62.6						
Twelve-month failure probability		not computable	0.07%			four consecutive discrete net-income quarters are required; found 4
Altman Z double-prime		(35.14)	(0.31)	84.1	756	2026-03-31
Net debt to EBITDA		not computable	1.82x			one or more required annual facts are missing
Interest coverage		not computable	(4.51x)			one or more required annual facts are missing
Current ratio		4.45x	2.96x	41.1	839	2026-03-31
Growth and financing						
Revenue growth, three-year compound		not computable	10.0%			four annual observations are required; found 3
Free cash flow growth, three-year compound		not computable	10.9%			four consecutive annual FCF observations are required; found 2
Reinvestment rate		not computable	37.1%			NOPAT must exceed \$100,000
Asset growth, three years		not computable	2.1%			four annual observations are required; found 3
Net share issuance, one year		not computable	2.5%			prior share count is 20 days earlier

Warnings

3 of 7 checks triggered; none of them enters the letter

Check	Measured
Short runway	cash runway is 3.1 months
Thin data	3 of 14 grade factors are computable; minimum is 7
Degenerate inputs	latest revenue or assets are at or below the \$100,000 validity floor

What the price implies

at the 2026-10-08 close; none enters the grade

Measure	Value	Peer median	Percentile
Twelve-month price change, skipping the latest month	(78.7%)	8.0%	4
Distance from 52-week high	(88.2%)	(31.4%)	5
EBIT to enterprise value	(1,643.6%)	(1.5%)	1
Free cash flow yield	(404.4%)	(1.0%)	3
Book value to price	1.04	0.28	87
Sales to price	0.00	0.31	0
Composite equity issuance, five years	not computable	20.3%	
Relative strength against the sector, log excess return	(1.76)	(0.14)	4

Diagnostics

not in the grade

Measure	Value
Piotroski F-score None of 9, period end 2026-03-31	
Return on assets above zero	fail
Operating cash flow above zero	fail
Return on assets improved	fail
Operating cash flow exceeds net income	pass
Long-term leverage fell	fail
Current ratio improved	fail
No new shares issued	fail
Gross margin improved	fail
Asset turnover improved	fail
Cash, filings, liquidity	
Cash and equivalents	\$3.5M
Operating cash flow, four quarters	-\$13.2M
Months of runway	3.1
Days since last periodic filing	57 (10-Q received Aug 13, 2026)
Median daily dollar volume, 63 sessions	\$625,045

Sources

each row links to the filing index on sec.gov

#	Concept	XBRL tag	Value	Period end	Received	Form	Accession
1	net income	us-gaap:NetIncomeLoss	-\$16.7M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
2	operating cash flow	us-gaap:NetCashProvidedByUsedInOperatingActivities	-\$12.3M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
3	assets	us-gaap:Assets	\$7.6M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
4	assets	us-gaap:Assets	\$9.8M	2025-03-31	2026-05-27	10-K	0001437749-26-018573
5	current assets	us-gaap:AssetsCurrent	\$7.6M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
6	current liabilities	us-gaap:LiabilitiesCurrent	\$1.7M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
7	retained earnings	us-gaap:RetainedEarningsAccumulatedDeficit	-\$67.1M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
8	operating income	us-gaap:OperatingIncomeLoss	-\$17.0M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
9	book equity	us-gaap:StockholdersEquity	\$5.9M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
10	liabilities	us-gaap:Liabilities	\$1.7M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
11	revenue	us-gaap:Revenues	\$0	2026-03-31	2026-05-27	10-K	0001437749-26-018573
12	revenue	us-gaap:Revenues	\$0	2025-03-31	2026-05-27	10-K	0001437749-26-018573
13	revenue	us-gaap:Revenues	\$0	2024-03-31	2025-05-29	10-K	0001437749-25-018831
14	capital expenditure	us-gaap:PaymentsToAcquirePropertyPlantAndEquipment	\$10,000	2026-03-31	2026-05-27	10-K	0001437749-26-018573
15	depreciation amortization	us-gaap:DepreciationDepletionAndAmortization	\$12,000	2026-03-31	2026-05-27	10-K	0001437749-26-018573
16	pretax income	us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsDeductibleItems	\$16.7M	2026-03-31	2026-05-27	10-K	0001437749-26-018573
17	income tax	us-gaap:IncomeTaxExpenseBenefit	\$0	2026-03-31	2026-05-27	10-K	0001437749-26-018573
18	current assets	us-gaap:AssetsCurrent	\$9.6M	2025-03-31	2026-05-27	10-K	0001437749-26-018573
19	current liabilities	us-gaap:LiabilitiesCurrent	\$1.7M	2025-03-31	2026-05-27	10-K	0001437749-26-018573
20	assets	us-gaap:Assets	\$9.4M	2024-03-31	2025-05-29	10-K	0001437749-25-018831
21	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,409,344	2026-06-10	2026-06-15	10-K/A	0001437749-26-020686
22	shares outstanding	dei:EntityCommonStockSharesOutstanding	11,409,344	2026-05-21	2026-05-27	10-K	0001437749-26-018573